Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Liraglutide has several non-glycemic effects, including those on plasma lipids and lipoproteins, contributing to its cardiovascular benefit; however, the exact underlying mechanisms remain unclear. We investigated a novel anti-atherogenic effect of liraglutide in a real-world prospective study on patients with type 2 diabetes (T2DM). METHODS: Sixty-two patients with T2DM (31 men, 31 women; mean age ± standard deviation 61 ± 9 years) naïve to incretin-based therapies were treated with liraglutide (1.2 mg/day) as add-on therapy to metformin (1500-3000 mg/day) for 4 months. Laboratory analyses included the assessment of lipoprotein subclass profile by gel electrophoresis (Lipoprint; Quantimetrix Corp., Redondo Beach, CA, USA). Carotid intima-media thickness (cIMT) was assessed by Doppler ultrasonography. Statistical analyses included the paired t test, Spearman correlation and multiple regression analysis. RESULTS: The addition of liraglutide to metformin monotherapy resulted in significant reductions in fasting glycemia, hemoglobin A1c, body mass index, waist circumference, total cholesterol, triglycerides and low-density lipoprotein (LDL)-cholesterol, as well as in cIMT. There was an increase in the large LDL-1 subfraction, with a concomitant reduction in atherogenic small dense LDL-3 and LDL-4 subfractions. Correlation analysis revealed a significant association between changes in cIMT and changes in small dense LDL-3 subfraction (r = 0.501; p < 0.0001). Multivariate analysis, including all of the measured anthropometric and laboratory parameters, revealed that only changes in the small dense LDL-3 subfraction were independent predictors of changes in cIMT (p < 0.0001). CONCLUSION: Our findings are the first to show that the vascular benefit of liraglutide in patients with T2DM is associated with reductions in atherogenic small dense LDL. This effect is independent of glycemic control and body weight reduction and may represent one of the key mechanisms by which liraglutide is able to reduce cardiovascular events. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01715428.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hence, by reducing sdLDL, there is less substrate available to be oxidized, and thus liraglutide may help slow down or prevent the atherosclerotic processes at an early stage and prevent ischemic stroke [43].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a prospective, real-world, 4-month study performed in 62 patients with T2DM, liraglutide also reduced the number of small dense LDL (sdLDL) particles, known to be highly atherogenic [43].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Liraglutide is also the first glucose-lowering drug in this class of medications that has shown cardiovascular (CV) benefit, as demonstrated in the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) study [2], and its beneficial microvascular and macrovascular effects have…”
BackgroundAlberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 852
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Hallberg, S. J., McKenzie, A. L., Williams, P. T., Bhanpuri, N. H., Peters, A. L., Campbell, W. W., Hazbun, T. L., Volk, B. M., McCarter, J. P., Phinney, S. D., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0373-9 · Cited by 406
Schernthaner, G., Matthews, D. R., Charbonnel, B., Hanefeld, M., & Brunetti, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030861 · Cited by 268
Keskitalo, K., Tuorila, H., Spector, T. D., Cherkas, L. F., Knaapila, A., Kaprio, J., Silventoinen, K., & Perola, M. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.2.263 · Cited by 223
Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss
Hyde, P. N., Sapper, T. N., Crabtree, C. D., LaFountain, R. A., Bowling, M. L., Buga, A., Fell, B., McSwiney, F. T., Dickerson, R. M., Miller, V. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128308 · Cited by 210 · cited 1×
“Previous studies [26, 27] have shown that ketogenic diets have very strong effects in terms of reliably reducing sdLDL.”
BackgroundP. Mikhailidis, D., Elisaf, M., Rizzo, M., Berneis, K., Griffin, B., Zambon, A., Athyros, V., de Graaf, J., Marz, W., G. Parhofer, K., et al. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111796642661 · Cited by 198
Self-citationChu, N. V., Kong, A. P. S., Kim, D. D., Armstrong, D., Baxi, S., Deutsch, R., Caulfield, M., Mudaliar, S. R., Reitz, R., Henry, R. R., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.542 · Cited by 196
Cited by
Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
“further investigated this association, demonstrating that this treatment regimen led to lower carotid intima-media thickness through reduction in atherogenic small dense LDL concentrations in 62 type 2 diabetic patients followed for 4 months [11].”
BackgroundResultVergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“In a prospective, real-world, 4-month study performed in 62 patients with T2DM, liraglutide also reduced the number of small dense LDL (sdLDL) particles, known to be highly atherogenic [43].”
BackgroundEffect of liraglutide on expression of inflammatory genes in type 2 diabetes
Zobel, E. H., Ripa, R. S., von Scholten, B. J., Rotbain Curovic, V., Kjaer, A., Hansen, T. W., Rossing, P., & Størling, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-97967-0 · Cited by 59
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Nikolic, D., Patti, A. M., Giglio, R. V., Chianetta, R., Castellino, G., Magán-Fernández, A., Citarrella, R., Papanas, N., Janez, A., Stoian, A. P., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01217-z · Cited by 38
Self-citation
Metadata
- Authors
- Nikolic, D., Giglio, R. V., Rizvi, A. A., Patti, A. M., Montalto, G., Maranta, F., Cianflone, D., Stoian, A. P., & Rizzo, M.
- Affiliations
- Istituto Euro Mediterraneo di Scienza e Tecnologia (IT)
- Emory University (US)
- University of Palermo (IT)
- Vita-Salute San Raffaele University (IT)
- Carol Davila University of Medicine and Pharmacy (RO)
- University of South Carolina (US)
- ORCID
- Venue
- Diabetes Therapy
- Published
- 2020-11-18
- Volume
- 12
- Issue
- 1
- Pages
- 261-274
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC7843804
- OpenAlex
- W3098397134
- Cited by
- 81
- References
- 50
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 9 · 2023: 11 · 2022: 19 · 2021: 13
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by-nc)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by-nc)
- Funders
- Università degli Studi di Palermo
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- liraglutide, type 2 diabetes, carotid intima-media thickness, small dense LDL, LDL subfractions, atherogenic lipoproteins, antiatherogenic effects, metformin add-on therapy, incretin-based therapy, cardiovascular risk reduction, dyslipidemia, real-world evidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect. https://app.cochat.ai/papers/10.1007/s13300-020-00962-3
- The paper
- Nikolic, D., Giglio, R. V., Rizvi, A. A., Patti, A. M., Montalto, G., Maranta, F., Cianflone, D., Stoian, A. P., & Rizzo, M. (2021). Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect. Diabetes Therapy. https://doi.org/10.1007/s13300-020-00962-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.